| Oncogenic Kras-driven pancreatic intraepithelial neoplasia originating in a non-ductal compartment can rapidly progress to pancreatic ductal adenocarcinoma when subjected to a brief inflammatory insult. | pancreatic, |
| These results strongly suggested that the oncogenic RAS upregulates EZH2 through MEK-ERK signaling, resulted in downregulation of tumor suppressors including RUNX3 in pancreatic carcinogenesis. | pancreatic, |
| Concurrent mutation in exons 1 and 2 of the K-ras oncogene in colorectal cancer. | colorectal, |
| Oncogenic KRAS can downregulate Bmp4 through a transcriptional pathway that depends on ERK. These findings point to a unique link between two pathways that are frequently altered in colon cancer. | colorectal, |
| Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. | sarcoma,breast, |
| studies demonstrate the requirement for Gli in Kras-dependent pancreatic epithelial transformation, suggest a mechanism of Gli-NF-kappaB oncogenic activation, and provide genetic evidence supporting therapeutic targeting of Gli activity in pancreatic cancer | pancreatic, |
| The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. | lung, |
| KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers. | prostate, |
| Oncogenic KRAS regulates 3D-specific miRNAs that are possibly associated with colorectal development in vivo. | colorectal, |
| Data show that an oncogenic Kras-dependent upregulation of GM-CSF in mouse pancreatic ductal epithelial cells (PDECs). | pancreatic, |
| Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. | breast, |
| Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene. | lung, |
| We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant | lung, |
| Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. | sarcoma, |
| EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. | pancreatic, |
| development of pancreatic ductal adenocarcinomas driven by K-Ras oncogenes are totally dependent on EGFR signaling; only loss of p53 made pancreatic tumors independent of EGFR signaling | pancreatic, |
| Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers. | endometrial, |
| findings show intratumoral heterogeneity of KRAS mutational status is rare in non-small cell lung cancer (NSCLC); finding is in line with hypothesis that oncogenic activation of KRAS is an early event and a bona fide driver mutation in NSCLC | lung, |
| Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells. | pancreatic, |
| Gene therapy of pancreatic cancer targeting the K-Ras oncogene. | pancreatic, |